These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 3135813)

  • 21. Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
    Illingworth DR; Bacon S
    Am J Cardiol; 1987 Oct; 60(12):33G-42G. PubMed ID: 3314447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-dependent effect of hydroxymethylglutaryl-coenzyme A reductase inhibitor on serum cholesterol with limited dietary restrictions: a case study.
    Okada S; Ichiki K; Tanokuchi S; Ota Z
    J Int Med Res; 1993; 21(2):105-11. PubMed ID: 8243790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental model of escape phenomenon in hamsters and the effectiveness of YM-53601 in the model.
    Ugawa T; Kakuta H; Moritani H; Shikama H
    Br J Pharmacol; 2002 Mar; 135(6):1572-8. PubMed ID: 11906972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
    Hsu I; Spinler SA; Johnson NE
    Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
    Maher VM; Thompson GR
    Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers.
    Nakaya N; Homma Y; Tamachi H; Goto Y
    Atherosclerosis; 1986 Aug; 61(2):125-8. PubMed ID: 3092836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
    Muratti EN; Peters TK; Leitersdorf E
    Am J Cardiol; 1994 May; 73(14):30D-38D. PubMed ID: 8198022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
    Pazzucconi F; Dorigotti F; Gianfranceschi G; Campagnoli G; Sirtori M; Franceschini G; Sirtori CR
    Atherosclerosis; 1995 Oct; 117(2):189-98. PubMed ID: 8801864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
    Leitersdorf E; Muratti EN; Eliav O; Peters TK
    Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Koga T; Shimada Y; Kuroda M; Tsujita Y; Hasegawa K; Yamazaki M
    Biochim Biophys Acta; 1990 Jul; 1045(2):115-20. PubMed ID: 2116173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
    Elmberger PG; Kalén A; Lund E; Reihnér E; Eriksson M; Berglund L; Angelin B; Dallner G
    J Lipid Res; 1991 Jun; 32(6):935-40. PubMed ID: 1940625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of pravastatin on serum cholesterol levels in hypercholesterolemic diabetic rabbits.
    Arbeeny CM; Bergquist KE
    Biochim Biophys Acta; 1991 Apr; 1096(3):238-44. PubMed ID: 1902119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.
    Kajinami K; Yagi K; Higashikata T; Inazu A; Koizumi J; Mabuchi H
    Am J Cardiol; 1998 Jul; 82(1):113-7. PubMed ID: 9671018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
    Tikkanen MJ; Helve E; Nikkilä EA
    Eur Heart J; 1987 Aug; 8 Suppl E():97-101. PubMed ID: 3315684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.
    Pan HY; DeVault AR; Swites BJ; Whigan D; Ivashkiv E; Willard DA; Brescia D
    Clin Pharmacol Ther; 1990 Aug; 48(2):201-7. PubMed ID: 2116260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [HMG-CoA-reductase inhibitors: a new principle in the treatment of hypercholesterolemia].
    Saxenhofer H; Weidmann P
    Ther Umsch; 1990 Jun; 47(6):509-13. PubMed ID: 2375007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors.
    Chong PH; Seeger JD
    Pharmacotherapy; 1997; 17(6):1157-77. PubMed ID: 9399600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of different HMG-CoA reductase inhibitors.
    Ditschuneit HH; Kuhn K; Ditschuneit H
    Eur J Clin Pharmacol; 1991; 40 Suppl 1():S27-32. PubMed ID: 1904357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.